The United States District Court for the Eastern District of Pennsylvania has approved a $158 million settlement in a lawsuit filed by parents and patients who claim that Johnson & Johnson’s Risperdal and Janssen Pharmaceuticals’ Invega caused them to develop tardive dyskinesia, also known as TD.
The “risperdal lawsuit update 2021” is a settlement that has been reached between the state of New York and GlaxoSmithKline.
(As of October 30, 2017)
In Risperdal litigation, there is a solid precedence for settlement. Johnson & Johnson, a pharmaceutical company, resolved more than 80 similar claims for unknown sums between 2012 and 2013. On November 2, 2016, the most recent secret settlement was reached.
In 2016, J&J was found guilty in three separate Risperdal cases that went to trial. The total amount awarded in these instances was approximately $5 million, with Austin Pledger earning $2.5 million (see “Pledger” below).
Even yet, they pale in contrast to Andrew Yount, who was given $70 million in July 2016 by a Philadelphia jury. J&J was found guilty of not only failing to warn Mr. Yount about the dangers of using Risperdal, but also of destroying evidence relating to the case.
Experts predict J&J will accept settlements in most Risperdal litigation to save time and money, given that thousands of these cases have yet to go to trial and the memory of these enormous judgments is still fresh in their memories.
A short history of Risperdal settlements is shown below.
Johnson & Johnson v. State of Texas (2012)
Johnson & Johnson agreed to pay $158 million in January 2012 to resolve a lawsuit brought by the State of Texas, claiming that J&J improperly marketed Risperdal to Medicaid recipients in the state.
“Johnson & Johnson’s attempt to profit from the Medicaid program by overstating the safety and efficacy of a costly medicine and inappropriately influencing authorities ended up costing taxpayers millions of dollars,” Texas Attorney General Greg Abbott said after the settlement.
Johnson & Johnson v. 36 States (2012)
Johnson & Johnson agreed to pay $181 million to 36 states and the District of Columbia in August 2012 to resolve fraud charges stemming from its illegal marketing of Risperdal. “In settling the charges by the states, Janssen did not acknowledge wrongdoing or that it violated the law, and claimed it resolved to avoid ‘unnecessary expenditure and a lengthy judicial procedure,’” according to the New York Times.
Johnson & Johnson v. Banks et al (2012)
At the age of nine, Aron Banks was given Risperdal off-label, and the medicine led him to develop breasts that had to be surgically removed. He was the first Risperdal plaintiff to have his case heard before a court of law. Johnson & Johnson resolved Mr. Banks’ claims for an unknown sum after just one day in court.
Following Mr. Banks’ case, there were five further instances that were deemed bellwethers. For each of them, J&J negotiated an undisclosed settlement.
Johnson & Johnson v. 77 Plaintiffs (2013)
Johnson & Johnson reached an undisclosed settlement with 77 more plaintiffs who had filed cases over Risperdal side effects in January 2013. The plaintiffs filed a request to enforce the settlement later that year, alleging that J&J had failed to respect its conditions and had no intention of doing so.
Johnson & Johnson v. United States Department of Justice (2013)
The FDA frequently cautioned J&J about advertising Risperdal for use by teenagers from 1999 to 2005. The Justice Department claims that Janssen pushed Risperdal for use in children and others with mental illnesses throughout this period. Risperdal caused “some health hazards to children, including the potential of raised prolactin levels, a hormone that might accelerate breast growth,” according to the firm.
A Justice Department investigation into Johnson & Johnson’s promotion and marketing of Risperdal resulted in a $2.2 billion fine in November 2013. This was one of the highest penalties in pharmaceutical history in the United States.
Johnson & Johnson v. State of Montana (2014)
Johnson & Johnson agreed to pay the State of Montana $5.9 million in March 2014 to resolve claims of illegal and misleading marketing in Texas, Washington, D.C., and 36 other jurisdictions.
Johnson & Johnson v. Pledger (2015)
Austin Pledger, an autistic kid from Alabama, developed breasts after being administered Risperdal off-label in 2002. (Risperdal was not approved for use by children by the FDA until 2006.) His friends teased him about his breasts, which ultimately ballooned to a size 46DD.
Mr. Pledger (now 21) has launched a lawsuit against J&J for their blatant concealing of Risperdal’s possible negative effects. Mr. Pledger was awarded $2.5 million in damages by a Philadelphia jury in February 2015.
Former FDA Commissioner David Kessler said during the trial that J&J knew as early as 2001 that Risperdal might induce gynecomastia in up to 5.5 percent of users, but did not add a warning to the drug’s label until 2006, five years later.
Johnson & Johnson v. State of South Carolina (2015)
The South Carolina Supreme Court concluded in February 2015 that J&J had to pay the state $136 million, affirming a previous verdict (one of several) that determined the medication company had illegally advertised Risperdal.
“Janssen’s ambition for market dominance and increasing sales knew no limitations,” Justice John Kittredge said in the verdict, “leading to its flagrant violation of South Carolina law.”
Murray v. Johnson & Johnson (Murray v. Johnson & Johnson) (2015)
Nicholas Murray (now 21) was administered Risperdal off-label for autistic symptoms from 2003 to 2008. Mr. Pledger, like so many others, developed gynecomastia as a result of the medicine. Mr. Murray’s breasts persisted when he stopped using the medicine.
A Philadelphia jury found against J&J one again in November 2015, this time in favor of Nicholas Murray. They awarded Mr. Murray $1.75 million in damages after just two hours of deliberation.
Johnson & Johnson v. Strange (2015)
Another jury decided against J&J in December 2015. The complainant this time was Timothy Strange, a Wisconsin man who was administered Risperdal as a youth (in 2006) to treat symptoms of Tourette syndrome. Mr. Strange was awarded $500,000 by the jury for J&J’s failure to warn him of the serious consequences of using Risperdal.
Johnson & Johnson v. Yount (2016)
A Philadelphia jury awarded Andrew Yount $70 million in July 2016, deciding that J&J not only failed to warn Mr. Yount about the hazards of taking Risperdal, but also that the firm had suppressed or destroyed evidence relating to the case.
Mr. Yount, a Tennessee resident, began taking Risperdal at the age of five. He, too, was affected by gynecomastia.
Johnson & Johnson v. Byrd (2017)
Shaquil Byrd, 24, of Troy, New York, was awarded $1 million by a jury in October 2017. Mr. Byrd was administered Risperdal when he was nine years old, and he acquired gynecomastia fast. His friends bullied him to the point that his breasts had to be surgically removed in 2014.
Have You Experienced Serious Side Effects?
With more than 350 lawyers on staff, our company is one of the biggest personal injury companies in the nation. We’ve earned $5 billion for our clients thus far.
Please contact us if you or a loved one has had unanticipated adverse effects after taking a medicine. Don’t put it off any longer; some situations are time-sensitive, and you might be due money.
Watch This Video-
The “risperdal lawsuit update 2021 philadelphia” is a news article about the Risperdal Lawsuit Settlement. The settlement was reached on December 31, 2018 and will provide $2 billion to individuals who were prescribed Risperdal over the course of its lifecycle between May 1, 2007 and December 31, 2017.
Frequently Asked Questions
What is the average payout for Risperdal lawsuit?
A: The average payout for the Risperdal lawsuit is $27,719.
What are the long term effects of risperidone?
A: Risperidone is a medication that has long-term effects of weight gain and high blood sugar. It can also cause nervousness, insomnia, dry mouth, or sedation.
What is the Risperdal lawsuit about?
A: Risperdal is a medication used to treat autism. In 2012, it was discovered that sales of the drug were significantly increased when this information became public knowledge because children who were prescribed Risperdal for use on their conditions would also be given methylphenidate or amphetamines as well. Many families sued GlaxoSmithKline for selling them fake drugs and won multi-million dollar settlements in 2016
- risperdal lawsuit update 2020
- johnson & johnson risperdal lawsuit update
- sanders phillips grossman risperdal settlement
- risperdal lawsuit deadline
- risperdal lawsuit update 2021 california